...
首页> 外文期刊>Kidney and blood pressure research >Treatment of Enterococcal Peritonitis in Peritoneal Dialysis Patients by Oral Amoxicillin or Intra-Peritoneal Vancomcyin: a Retrospective Study
【24h】

Treatment of Enterococcal Peritonitis in Peritoneal Dialysis Patients by Oral Amoxicillin or Intra-Peritoneal Vancomcyin: a Retrospective Study

机译:口服阿莫西林或腹膜内万古霉素治疗腹膜透析患者肠球菌性腹膜炎的回顾性研究

获取原文
           

摘要

Background/Aims: Enterococcal peritonitis in peritoneal dialysis (PD) patients is associated with a high complication rate. The optimal treatment regimen of PD-related enterococcal peritonitis is controversial. The latest international guideline recommends intra-peritoneal (IP) vancomycin. Although ampicillin is often effective for systemic enterococcal infections, they have little in vitro activity when added to common PD solutions. Since oral amoxicillin achieves therapeutic drug level in the peritoneal cavity, we explore the efficacy of oral amoxicillin for enterococcal peritonitis. Methods: We studied 105 episodes of enterococcal peritonitis over 20 years in our unit; 43 (41.0%) were treated with oral amoxicillin, and 62 (59.0%) with IP vancomycin. Their clinical outcome was reviewed. Result: The overall primary response rate to oral amoxicillin and IP vancomycin was 76.4% and 85.5%, respectively (p = 0.3). The complete cure rate of oral amoxicillin and IP vancomycin was 55.8% and 54.8%, respectively (p = 0.8). When the 5 episodes of ampicillin-resistant Enterococcus episodes were excluded, the primary response rate and complete cure rate of oral amoxicillin were 86.8% and 63.2%, respectively. Conclusion: Oral amoxicillin has an excellent primary response rate and complete cure rate for PD-related peritonitis episodes caused by Enterococcus species, indicating that oral amoxicillin is a valid and convenient therapeutic option for enterococcal peritonitis episodes.
机译:背景/目的:腹膜透析(PD)患者的肠球菌性腹膜炎与高并发症发生率相关。 PD相关性肠球菌性腹膜炎的最佳治疗方案尚存争议。最新的国际指南推荐腹膜内(万古霉素)。尽管氨苄西林通常对全身性肠球菌感染有效,但当添加到常见的PD溶液中时,它们的体外活性很小。由于口服阿莫西林在腹膜腔内达到治疗药物水平,因此我们探讨了口服阿莫西林对肠球菌性腹膜炎的疗效。方法:我们研究了20年间105例肠球菌性腹膜炎的发作;口服阿莫西林治疗43例(41.0%),IP万古霉素治疗62例(59.0%)。他们的临床结果进行了审查。结果:口服阿莫西林和IP万古霉素的总体主要缓解率分别为76.4%和85.5%(p = 0.3)。口服阿莫西林和IP万古霉素的完全治愈率分别为55.8%和54.8%(p = 0.8)。排除5例氨苄西林耐药肠球菌事件后,口服阿莫西林的主要缓解率和完全治愈率分别为86.8%和63.2%。结论:口服阿莫西林对肠球菌引起的PD相关性腹膜炎发作具有优异的初次应答率和完全治愈率,表明口服阿莫西林是治疗肠球菌性腹膜炎发作的有效且方便的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号